Do you want to read an article? Please log in or register.
Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study
Genitourinary Cancer
Related content
Genitourinary Cancer
Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial
Eur J Cancer
Tombal B, Hussain M, Saad F, Fizazi K, Shore N, Kopyltsov E, Bögemann M, Mendez-Vidal MJ, Littleton N, Srinivasan S, Verholen F, Smith MR
doi: 10.1016/j.ejca.2026.116730
Genitourinary Cancer
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial
Eur J Cancer
Fizazi K, Smith MR, Hussain M, Saad F, Sternberg CN, David Crawford E, Aragon-Ching JB, Schostak M, Tutrone R, Morgans AK, Sentana-Lledo D, Joensuu H, Mohamed AF, Littleton N, Srinivasan S, Buttkewitz Y, Li R, Kuss I, Tombal B
doi: 10.1016/j.ejca.2026.116888
Genitourinary Cancer
Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study
Urol Oncol
Rinderknecht E, Bielstein G, Cathomas R, Schlack K, Bastian JLD, Darr C, Unland-Gies D, Kappler P, Paffenholz P, Richter J, Müller M, Seitz AK, Steinestel J, Heidegger I, Burger M, Breyer J, Schnabel MJ
doi: 10.1016/j.urolonc.2026.111028
Lung, Respiratory and Thoracic Cancer
Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study
Lung Cancer
Kato T, Dong X, Takahashi T, Soparattanapaisarn N, Geater SL, Wang CL, Arriola E, Moiseenko F, Thompson L, Grainger E, Armenteros-Monterroso E, Evans A, Bolanos A, Ramalingam SS, Lu S
doi: 10.1016/j.lungcan.2026.109486
CHICAGO 2026
Multiple Myeloma (MM)
DREAMM-9: High efficacy of belamaf in combination with VRd across all dosing cohorts in transplant-ineligible NDMM
Myelodysplastic syndromes
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study
J Clin Oncol
Sallman DA, Garcia-Manero G, Daver N, Abboud CN, Stein E, Larkin K, Halpern AB, McCurdy SR, Al Malki MM, Subramanian Guru Murthy G, Silverman LR, Larson RA, Greenberg P, Gojo I, Wrobel T, Platzbecker U, Forsyth C, Vachhani P, Dong M, Shao J, Johnson LDS, Tan A, Lee C, Doshi P, Vyas P, Wei AH
doi: 10.1200/JCO-25-00617
ESMO 2025
Genitourinary Cancer
ARASAFE: Lower docetaxel dose improves safety in patients with mHSPC
Lung, Respiratory and Thoracic Cancer
The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study
Lung Cancer
Rolfo C, Gerber DE, Kotecha R, Ward JP, Akerley W, Weiss L, Naveh A, Shapira N, Leal T, Langer CJ, LUNAR study investigators
doi: 10.1016/j.lungcan.2025.108802
COMMENTED
Further Publications
Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase III trial in non-invasive breast cancer
★ 1
Recommended and commented by
Dr Andreas Müller, Faculty Member
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Natl Cancer Inst
Carbone A, Oliva M, Puntoni M, Guerrieri-Gonzaga A, Briata IM, Lazzeroni M, Serrano D, Giordano L, Digennaro M, Cortesi L, Millo F, Cagossi K, Aprile G, Serra P, Gallerani E, Bonanni B, DeCensi A
doi: 10.1093/jnci/djaf250